Mar 25th 2022
Takeda’s ALUNBRIG® (brigatinib) approved by China’s NMPA as a new treatment option for patients with ALK-positive non-small cell lung cancer
Media Materials
If you are a journalist or member of the media looking for Takeda Oncology resources, visit the media materials section of our newsroom